CN113831400A - Separation and purification method of dust mite allergenic protein Der p 1 - Google Patents
Separation and purification method of dust mite allergenic protein Der p 1 Download PDFInfo
- Publication number
- CN113831400A CN113831400A CN202110877852.9A CN202110877852A CN113831400A CN 113831400 A CN113831400 A CN 113831400A CN 202110877852 A CN202110877852 A CN 202110877852A CN 113831400 A CN113831400 A CN 113831400A
- Authority
- CN
- China
- Prior art keywords
- dust mite
- protein
- solution
- buffer solution
- der
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000428 dust Substances 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 title claims abstract description 39
- 108010061629 Dermatophagoides pteronyssinus antigen p 1 Proteins 0.000 title claims abstract description 37
- 238000000926 separation method Methods 0.000 title claims abstract description 13
- 238000000746 purification Methods 0.000 title claims abstract description 10
- 230000002009 allergenic effect Effects 0.000 title claims abstract description 6
- 239000000243 solution Substances 0.000 claims abstract description 66
- 239000012148 binding buffer Substances 0.000 claims abstract description 35
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 35
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 35
- 238000010828 elution Methods 0.000 claims abstract description 18
- 239000012149 elution buffer Substances 0.000 claims abstract description 17
- 239000013566 allergen Substances 0.000 claims abstract description 16
- 239000007974 sodium acetate buffer Substances 0.000 claims abstract description 16
- 238000005277 cation exchange chromatography Methods 0.000 claims abstract description 13
- 239000000287 crude extract Substances 0.000 claims abstract description 13
- 238000011068 loading method Methods 0.000 claims abstract description 10
- 239000000047 product Substances 0.000 claims abstract description 10
- 239000006228 supernatant Substances 0.000 claims abstract description 9
- 239000000284 extract Substances 0.000 claims abstract description 8
- 238000005406 washing Methods 0.000 claims abstract description 7
- 230000000774 hypoallergenic effect Effects 0.000 claims abstract description 6
- 229960005486 vaccine Drugs 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 230000001235 sensitizing effect Effects 0.000 claims description 16
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 4
- 230000003449 preventive effect Effects 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 abstract description 5
- 208000010668 atopic eczema Diseases 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 22
- 241000238876 Acari Species 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 9
- 239000003480 eluent Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 5
- 206010002198 Anaphylactic reaction Diseases 0.000 description 4
- 208000003455 anaphylaxis Diseases 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 101000609447 Beet necrotic yellow vein virus (isolate Japan/S) Protein P25 Proteins 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 208000035533 House dust allergy Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 229940062713 mite extract Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Insects & Arthropods (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a separation and purification method of dust mite allergenic protein Der p 1, which comprises the following steps: 1) preparing a coarse extract of dust mite water-soluble protein: adding PBS-T solution into dust sample containing dust mite, stirring overnight at 4 deg.C, centrifuging at 5000 × g, and collecting supernatant; adding sodium acetate buffer solution into the supernatant, dialyzing at 4 deg.C for 3-4 days, and storing at 4 deg.C; 2) cation exchange chromatography: loading the crude extract of the dust mite water soluble protein prepared in the step 1), washing by using a binding buffer solution, fixing the binding buffer solution, performing gradient elution by using an elution buffer solution, and collecting an elution peak to obtain a target product. The method has the characteristics of high speed, high efficiency, stable production, low cost and the like; the prepared extracting solution or purified protein can be used for detecting main allergic protein in a serum sample of a patient, and meanwhile, the recombinant allergen can be further prepared, and the method has wide application in the aspects of designing hypoallergenic derivatives and preventing vaccines.
Description
Technical Field
The invention relates to the technical field of separation and purification of proteins, in particular to a separation and purification method of dust mite sensitizing protein Der p 1.
Background
Allergic diseases comprise allergic asthma, allergic rhinitis, food allergy and the like, and are clinically common diseases and frequently encountered diseases. Allergies are caused by the immune response of the body to large molecular (e.g. proteinaceous) substances that are normally harmless. Dust mites are one of the leading causes of allergic diseases worldwide. Dust mites cause allergic diseases of the respiratory system such as allergic asthma and rhinitis, and in 2004, the world health organization estimates about 3 billion patients with asthma and rhinitis worldwide and is on the rise (Chen K W, Hypoallengenic Der p 1/Der p 2combination vaccines for immunological therapy of house dust mite allergy, 2012). The content of Der p 1 in house dust mite is 0.02-14.30 μ g/g, the amino acid number of Der p 1 is 320, it is glycoprotein with molecular weight of 25kDa, and isoelectric point is 4.7-7.4. In the secondary structure of Der p 1, 43.75% is alpha helical structure, and as a papain family member, the papain family member contains active sites such as histidine, cysteine, aspartic acid, magnesium binding site and the like, and plays a key role in the process of generating anaphylactic reaction with later stage. However, the special extraction processes developed for dust mites, including long extraction processes, may lead to degradation and aggregation of glycoproteins.
Therefore, in order to reduce the risk of introducing any possible artefacts at the level of the major allergens, the present application has developed a rapid extraction method, resulting in a major allergen enrichment and formulated a separation and purification method aimed at obtaining a suitable amount of the 25kDa allergen.
Disclosure of Invention
The technical problem to be solved by the invention is to provide a method for separating and purifying dust mite sensitizing protein Der p 1, which solves the problems in the prior art.
The technical problem to be solved by the invention is realized by the following technical scheme:
a method for separating and purifying dust mite sensitizing protein Der p 1 comprises the following steps:
1) preparing a coarse extract of dust mite water-soluble protein: adding PBS-T solution into dust sample containing dust mite, stirring overnight at 4 deg.C, centrifuging at 5000 × g, and collecting supernatant; adding sodium acetate buffer solution into the supernatant, dialyzing at 4 deg.C for 3-4 days, and storing at 4 deg.C;
2) cation exchange chromatography: loading the crude extract of the dust mite water soluble protein prepared in the step 1), washing by using a binding buffer solution, fixing the binding buffer solution, performing gradient elution by using an elution buffer solution, and collecting an elution peak to obtain a target product.
Preferably, the method further comprises the following steps:
3) freeze-drying: and (3) carrying out freeze-drying treatment on the target product in the step 2) to obtain a pure product of the dust mite allergenic protein Der p 1.
Preferably, in the step 1), the solid-to-liquid ratio of the dust sample containing dust mites to the PBS-T solution is 1: (100-.
Preferably, the binding buffer in the step 2) is 10-100mM sodium acetate buffer with pH 4.5.
Preferably, the elution buffer solution in the step 2) is 100-1000 mM NaCl solution.
Preferably, step 2) is specifically:
21) preparing a binding buffer solution and an elution buffer solution, filtering and storing at room temperature;
22) loading, eluting and collecting: washing the system pump with 20% ethanol, connecting the column to the chromatography system, washing the sample pump with binding buffer, and balancing the column with 2 column volumes of binding buffer; sample is loaded through a sample pump, the sample injection volume is 1mL, after sample injection is carried out for 5min, the column is washed by 1 column volume binding buffer, then gradient elution is carried out on the column by using 0-30% elution buffer, 10 column volumes are washed, and after the elution is finished, the column is balanced by using the binding buffer, and 5 column volumes are balanced.
Preferably, the binding buffer solution is 10-100mM sodium acetate buffer solution with pH 4.5, the solution is filtered by 0.2 μm filter paper after being prepared, and is stored at room temperature for later use; the elution buffer solution is 100-1000 mM NaCl solution, and the solution is prepared, filtered by 0.2 mu m filter paper and stored at room temperature for later use.
Preferably, the method further comprises identifying the Der p 1 protein by SDS-PAGE from the elution peaks collected in step 2).
A dust mite sensitizing protein Der p 1 prepared by the method for separating and purifying the dust mite sensitizing protein Der p 1.
An application of the dust mite sensitizing protein Der p 1 prepared by the method for separating and purifying the dust mite sensitizing protein Der p 1 in preparing recombinant allergens, hypoallergenic derivatives and preventive vaccines.
The technical scheme of the invention has the following beneficial effects:
(1) according to the separation and purification method of the main allergic protein, the content of the main allergic protein Der p 1 in the dust mite crude extract can be obviously improved by improving the components of the dust mite protein extract, and then the target protein in the dust mite crude extract is separated and purified through cation exchange chromatography, so that 25kDa allergen with high purity and proper quantity is obtained.
(2) The method for detecting the allergen in vitro, namely ImonoCAP, used in clinic at present does not contain Der p 1, and the invention is beneficial to applying crude extract or purified protein of the protein to preparation of recombinant allergen, design of hypoallergenic derivatives and preventive vaccination and is expected to develop a new generation of candidate drugs for desensitization treatment.
Drawings
The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description, serve to explain the principles of the invention.
FIG. 1 shows the distribution of major proteins in the crude extract of dust mites of this application. Wherein, Lane 1: protein marker; lane 2: dust mite extract.
FIG. 2 is the results of cation exchange chromatography in accordance with the present application. Arrows indicate the collection peak containing the protein of interest.
FIG. 3 shows the results of cation exchange chromatography SDS-PAGE according to the present application. Wherein, M: protein marker; lane 1 is collection I; lane 2 is collection II; wherein Lane 3 is a 25kDa protein band (i.e., the target protein) visible on SDS-PAGE of the collection III; lane 4 is collection IV; lane 5 is pool V.
Detailed Description
Various exemplary embodiments of the present invention will now be described in detail with reference to the accompanying drawings. It should be noted that: the relative arrangement of the components and steps, the numerical expressions and numerical values set forth in these embodiments do not limit the scope of the present invention unless specifically stated otherwise.
Example 1
Dust mite raw materials: dust samples containing dust mites were provided by the university of medical, california.
The operation method comprises the following steps: the conventional operation method adopted by the application is detailed in Experimental anaphylaxis, Yangshao Heng, 2010.
(1) Preparation of a crude extract: a dust mite-containing dust sample (0.10 g) was weighed, added to 20mL of PBS-T solution, stirred overnight at 4 ℃, and the supernatant was collected by centrifugation at 5000 Xg for 20min, to which 20mL of 10-100mM sodium acetate buffer solution (pH 4.5) was added, dialyzed, and dialyzed at 4 ℃ for 3-4 days. After dialysis, the cells were stored at 4 ℃. The distribution of main proteins in the coarse extract of dust mites extracted by the method is shown in figure 1.
The allergen protein in the dust mite is subjected to crude extraction by adopting a PBS-T solution, and is dialyzed by using a 10-100mM sodium acetate buffer solution with pH 4.5, so that the target allergen protein Der p 1 in the dust mite crude extract has the highest content (25.0kDa) and other proteins have lower contents.
(2) Cation exchange chromatography:
21) solution preparation:
binding buffer: 10-100mM sodium acetate buffer solution with pH 4.5, filtering the solution with 0.2 μm filter paper, and storing at room temperature.
Elution buffer: filtering the solution with 100-1000 mM NaCl and 0.2 μm filter paper, and storing at room temperature.
22) Loading, eluting and collecting: the system pump was first washed with 20% ethanol, then a HiTrap Capto MMC (1ml, GE Healthcare) column was attached to the AKTA pure instrument, the sample pump was washed with binding buffer, and the column was equilibrated with 2 column volumes of binding buffer. Sample loading is carried out through a sample pump, the sample injection volume is 1mL, after sample injection is carried out for 5min, the column is washed by 1 column volume binding buffer, then gradient elution is carried out on the column by using 30% elution buffer, 10 column volumes are washed, after the elution is finished, the column is balanced by using the binding buffer, and 5 column volumes are balanced. Collecting the target eluent to obtain the target product.
The results of cation exchange chromatography are shown in FIG. 2, in which the arrow indicates the peak containing the target protein, and the peak III pool is selected.
(3) Different eluents were selected according to the collected peaks for SDS-PAGE electrophoresis to analyze the protein separation effect.
The peak III pools were selected for SDS-PAGE analysis, as shown in FIG. 3, wherein a distinct 25kDa protein band (i.e., the protein of interest) was observed on SDS-PAGE in the peak III pools.
Example 2
Dust mite raw materials: dust samples containing dust mites were provided by the university of medical, california.
The operation method comprises the following steps: the conventional operation method adopted by the application is detailed in Experimental anaphylaxis, Yangshao Heng, 2010.
(1) Preparation of a crude extract: a dust mite-containing dust sample (0.10 g) was weighed, added to 10mL of PBS-T solution, stirred overnight at 4 ℃, and the supernatant was collected by centrifugation at 5000 Xg for 20min, to which 20mL of 10-100mM sodium acetate buffer solution (pH 4.5) was added, dialyzed, and dialyzed at 4 ℃ for 3-4 days. After dialysis, the cells were stored at 4 ℃.
(2) Cation exchange chromatography:
21) solution preparation:
binding buffer: 10-100mM sodium acetate buffer solution with pH 4.5, filtering the solution with 0.2 μm filter paper, and storing at room temperature.
Elution buffer: filtering the solution with 100-1000 mM NaCl and 0.2 μm filter paper, and storing at room temperature.
22) Loading, eluting and collecting: the system pump was first washed with 20% ethanol, then a HiTrap Capto MMC (1ml, GE Healthcare) column was attached to the AKTA pure instrument, the sample pump was washed with binding buffer, and the column was equilibrated with 2 column volumes of binding buffer. Sample loading is carried out through a sample pump, the sample injection volume is 1mL, after sample injection is carried out for 5min, the column is washed by 1 column volume binding buffer, then gradient elution is carried out on the column by using 30% elution buffer, 10 column volumes are washed, after the elution is finished, the column is balanced by using the binding buffer, and 5 column volumes are balanced. Collecting the target eluent to obtain the target product.
(3) Different eluents were selected according to the collected peaks for SDS-PAGE electrophoresis to analyze the protein separation effect.
Example 3
Dust mite raw materials: dust samples containing dust mites were provided by the university of medical, california.
The operation method comprises the following steps: the conventional operation method adopted by the application is detailed in Experimental anaphylaxis, Yangshao Heng, 2010.
(1) Preparation of a crude extract: a dust mite-containing dust sample (0.10 g) was weighed, added to 15mL of PBS-T solution, stirred overnight at 4 ℃, and the supernatant was collected by centrifugation at 5000 Xg for 20min, to which 20mL of 10-100mM sodium acetate buffer solution (pH 4.5) was added, dialyzed, and dialyzed at 4 ℃ for 3-4 days. After dialysis, the cells were stored at 4 ℃.
(2) Cation exchange chromatography:
21) solution preparation:
binding buffer: 10-100mM sodium acetate buffer solution with pH 4.5, filtering the solution with 0.2 μm filter paper, and storing at room temperature.
Elution buffer: filtering the solution with 100-1000 mM NaCl and 0.2 μm filter paper, and storing at room temperature.
22) Loading, eluting and collecting: the system pump was first washed with 20% ethanol, then a HiTrap Capto MMC (1ml, GE Healthcare) column was attached to the AKTA pure instrument, the sample pump was washed with binding buffer, and the column was equilibrated with 2 column volumes of binding buffer. The sample is loaded through a sample pump, the sample injection volume is 1mL, after the sample injection is carried out for 5min, the column is washed by 1 column volume binding buffer, then the column is subjected to gradient elution by using 0-30% elution buffer, 10 column volumes are washed, and after the elution is finished, the column is balanced by using the binding buffer, and 5 column volumes are balanced. Collecting the target eluent to obtain the target product.
(3) Different eluents were selected according to the collected peaks for SDS-PAGE electrophoresis to analyze the protein separation effect.
And (4) analyzing results:
(1) preparation of a crude extract: by adopting PBS-T solution to carry out rough extraction on the allergen protein in the dust mites and dialyzing the dust mites by using 10-100mM sodium acetate buffer solution with pH 4.5, the content of the target allergen protein Der p 1 in the dust mite rough extract is the highest (25.0kDa), while the content of other proteins is less, the operation is green, mild, simple and easy to implement, and the protein is not easy to degrade, wherein the target allergen protein is the main protein component of the extract. The distribution of main proteins in the coarse extract of dust mites extracted by the method is shown in figure 1.
(2) Cation exchange chromatography: the results of cation exchange chromatography are shown in FIG. 2, in which the arrow indicates the peak containing the target protein, and the peak III pool is selected.
(3) SDS-PAGE electrophoresis: the peak III pools were selected for SDS-PAGE analysis, as shown in FIG. 3, wherein a distinct 25kDa protein band (i.e., the protein of interest) was observed on SDS-PAGE in the peak III pools.
The dust mite sensitizing protein Der p 1 obtained by the separation and purification method according to the above embodiment can be applied in various fields, such as the preparation of recombinant allergens, hypoallergenic derivatives and prophylactic vaccines. This will be a major direction for future exploration.
Fig. 1, 2 and 3 are graphs showing the results of example 1. The results of the embodiments 2 and 3 are similar to those of the embodiment 1, and are not repeated herein.
Therefore, the invention provides a method for separating and purifying the main allergic protein Der p 1 of dust mites. The separation and purification method comprises the steps of preparing a dust mite water soluble protein crude extract, further separating and purifying by cation exchange chromatography HiTrap Capto obtain a purified main allergenic protein Der p 1 by using a pH 4.5 sodium acetate buffer solution as a binding solution (10-100 mM) and a 30% NaCl solution (100-1000 mM NaCl) as an eluent. The method has the characteristics of high speed, high efficiency, stable production, low cost and the like. The prepared extracting solution or purified protein can be used for detecting main allergic protein in a serum sample of a patient, and meanwhile, the recombinant allergen can be further prepared, and the method has wide application in the aspects of designing hypoallergenic derivatives and preventing vaccines.
Although the present invention has been described with reference to the above embodiments, it should be understood that the present invention is not limited thereto, and various changes and modifications may be made by those skilled in the art without departing from the spirit and scope of the present invention.
Claims (10)
1. A separation and purification method of dust mite sensitization protein Der p 1 is characterized by comprising the following steps:
1) preparing a coarse extract of dust mite water-soluble protein: adding PBS-T solution into dust sample containing dust mite, stirring overnight at 4 deg.C, centrifuging at 5000 × g, and collecting supernatant; adding sodium acetate buffer solution into the supernatant, dialyzing at 4 deg.C for 3-4 days, and storing at 4 deg.C;
2) cation exchange chromatography: loading the crude extract of the dust mite water soluble protein prepared in the step 1), washing by using a binding buffer solution, fixing the binding buffer solution, performing gradient elution by using an elution buffer solution, and collecting an elution peak to obtain a target product.
2. The method for separating and purifying a dust mite sensitizing protein Der p 1 as claimed in claim 1, further comprising:
3) freeze-drying: freeze-drying the target product obtained in the step 2) to obtain a pure product of the dust mite allergenic protein Der p 1.
3. The method for separating and purifying a dust mite-sensitized protein Der p 1 according to claim 1, wherein in the step 1), the solid-to-liquid ratio of the dust mite-containing dust sample to the PBS-T solution is 1 (100-200).
4. The method for separating and purifying a dust mite sensitizing protein Der p 1 as claimed in claim 1, wherein the binding buffer in the step 2) is a sodium acetate buffer solution with a pH of 10 to 100mM and 4.5.
5. The method for separating and purifying a dust mite sensitized protein Der p 1 according to claim 1, wherein the elution buffer solution in the step 2) is 100 to 1000mM NaCl solution.
6. The method for separating and purifying the dust mite sensitizing protein Der p 1 according to claim 1, wherein the step 2) is specifically as follows:
21) preparing a binding buffer solution and an elution buffer solution, filtering and storing at room temperature;
22) loading, eluting and collecting: washing the system pump with 20% ethanol, connecting the column to the chromatography system instrument, washing the sample pump with binding buffer, and equilibrating the column with 2 column volumes of binding buffer; sample is loaded through a sample pump, the sample injection volume is 1mL, after sample injection is carried out for 5min, the column is washed by 1 column volume binding buffer, then gradient elution is carried out on the column by using 0-30% elution buffer, 10 column volumes are washed, and after the elution is finished, the column is balanced by using the binding buffer, and 5 column volumes are balanced.
7. The method for separating and purifying the dust mite sensitized protein Der p 1 according to claim 1, wherein the binding buffer solution is a 10-100mM sodium acetate buffer solution with pH 4.5, the solution is prepared and filtered by 0.2 μm filter paper, and the solution is stored at room temperature for later use; the elution buffer solution is 100-1000 mM NaCl solution, and the solution is prepared, filtered by 0.2 mu m filter paper and stored at room temperature for later use.
8. The method for separating and purifying a dust mite sensitizing protein Der p 1 as claimed in claim 1, further comprising identifying the Der p 1 protein by SDS-PAGE from the elution peaks collected in the step 2).
9. A dust mite sensitizing protein Der p 1 prepared by the method for separating and purifying the dust mite sensitizing protein Der p 1 according to any one of claims 1 to 8.
10. An application of the dust mite sensitizing protein Der p 1 prepared by the method for separating and purifying the dust mite sensitizing protein Der p 1 according to any one of claims 1-8 in preparing recombinant allergens, hypoallergenic derivatives and preventive vaccines.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110877852.9A CN113831400A (en) | 2021-07-29 | 2021-07-29 | Separation and purification method of dust mite allergenic protein Der p 1 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110877852.9A CN113831400A (en) | 2021-07-29 | 2021-07-29 | Separation and purification method of dust mite allergenic protein Der p 1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113831400A true CN113831400A (en) | 2021-12-24 |
Family
ID=78963108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110877852.9A Pending CN113831400A (en) | 2021-07-29 | 2021-07-29 | Separation and purification method of dust mite allergenic protein Der p 1 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113831400A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060002948A1 (en) * | 2004-07-01 | 2006-01-05 | Biomay Produktions- Und Handels-Aktiengesellschaft | Allergen from house-dust mites |
| CN1763174A (en) * | 2005-08-26 | 2006-04-26 | 中国医学科学院北京协和医院 | The preparation method of the cultivation collection of dermatophagoides pteronyssinus and anaphylactogen diagnosis thereof and treatment preparation |
| CN101977929A (en) * | 2008-03-25 | 2011-02-16 | 拜尔工业制药有限公司 | Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies |
| CN103748105A (en) * | 2011-06-15 | 2014-04-23 | 生物技术工具公司 | A method for the production of hydrolyzed allergens |
| CN106282213A (en) * | 2015-06-03 | 2017-01-04 | 深圳北京大学香港科技大学医学中心 | A kind of method expressing also purification of soluble dermatophagoides pteronyssinus main allergen Der p 2 albumen |
-
2021
- 2021-07-29 CN CN202110877852.9A patent/CN113831400A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060002948A1 (en) * | 2004-07-01 | 2006-01-05 | Biomay Produktions- Und Handels-Aktiengesellschaft | Allergen from house-dust mites |
| CN1763174A (en) * | 2005-08-26 | 2006-04-26 | 中国医学科学院北京协和医院 | The preparation method of the cultivation collection of dermatophagoides pteronyssinus and anaphylactogen diagnosis thereof and treatment preparation |
| CN101977929A (en) * | 2008-03-25 | 2011-02-16 | 拜尔工业制药有限公司 | Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies |
| CN103748105A (en) * | 2011-06-15 | 2014-04-23 | 生物技术工具公司 | A method for the production of hydrolyzed allergens |
| CN106282213A (en) * | 2015-06-03 | 2017-01-04 | 深圳北京大学香港科技大学医学中心 | A kind of method expressing also purification of soluble dermatophagoides pteronyssinus main allergen Der p 2 albumen |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rodríguez et al. | Allergenic diversity of the olive pollen | |
| EP0011032B1 (en) | Method for isolation of hbsag | |
| CN101638427B (en) | Method for purifying virus antigens | |
| CN87104828A (en) | Be used as Neisseria gonorrhoeae lectin hemoglutinin of vaccine and diagnostic flag and preparation method thereof | |
| EP0138167B1 (en) | Method for purification of hbs antigen | |
| EP0175841B1 (en) | Method for the production of pertussis component vaccine and combined vaccine of pertussis antigen; diphtheria toxoid and tetanus toxoid | |
| CN113831400A (en) | Separation and purification method of dust mite allergenic protein Der p 1 | |
| US20080118991A1 (en) | Method for isolating and purifying grass pollen allergens | |
| CN108059673B (en) | Method for separating immunoglobulin IgG from human serum | |
| CN101392017B (en) | Isolation and purification method of main allergic protein of humulus pollen | |
| CN101392023B (en) | Main allergic protein of humulus pollen | |
| Spies et al. | The Chemistry of Allergens. II. Isolation and Properties of an Active Protein Component of Cottonseed1 | |
| CN113683693B (en) | Preparation method and application of house dust mite allergen specific IgG Fab antibody fragment | |
| CA1243014A (en) | Tissue protein pp in21 xx, a process for obtaining it and its use | |
| JP2001521907A (en) | Tolerogenic fragments of natural allergens | |
| CN101392022B (en) | Monoclonal antibody of main allergic protein of humulus pollen | |
| CN116410275A (en) | Recombinant artemisia annua pollen I allergen and preparation method and application thereof | |
| CN110698548B (en) | Cordyceps militaris active protein CMPr and preparation method and application thereof | |
| CN106749590A (en) | A kind of method for isolating and purifying rosy clouds medusocongestin albumen | |
| JP5174312B2 (en) | Method for purifying recombinant proteins expressed as insoluble aggregates | |
| Napoleão et al. | Affinity matrices of Cratylia mollis seed lectins for isolation of glycoproteins from complex protein mixtures | |
| Idar et al. | Purification of IgY Anti-SARS-CoV-2-Chicken Nucleocapsid and Elimination of Its Low-temperature Storage-induced Aggregates | |
| CN108129558B (en) | Extraction, separation and purification method and application of main allergenic protein Bet v8 of birch pollen | |
| CN1206240C (en) | High efficiency ionic exchange membrane chromatography decontamination vitelloenin technology | |
| Seitzer et al. | Characterization of immunoglobulin E responses in Balb/c mice against the major allergens of timothy grass (Phleum pratense) pollen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |